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Abstract: The disability-adjusted life year (DALY) initially
appeared attractive as a health metric in the Global
Burden of Disease (GBD) program, as it purports to be a
comprehensive health assessment that encompassed
premature mortality, morbidity, impairment, and disabil-
ity. It was originally thought that the DALY would be
useful in policy settings, reflecting normative valuations as
a standardized unit of ill health. However, the design of
the DALY and its use in policy estimates contain inherent
flaws that result in systematic undervaluation of the
importance of chronic diseases, such as many of the
neglected tropical diseases (NTDs), in world health. The
conceptual design of the DALY comes out of a
perspective largely focused on the individual risk rather
than the ecology of disease, thus failing to acknowledge
the implications of context on the burden of disease for
the poor. It is nonrepresentative of the impact of poverty
on disability, which results in the significant underestima-
tion of disability weights for chronic diseases such as the
NTDs. Finally, the application of the DALY in policy
estimates does not account for the nonlinear effects of
poverty in the cost-utility analysis of disease control,
effectively discounting the utility of comprehensively
treating NTDs. The present DALY framework needs to
be substantially revised if the GBD is to become a valid
and useful system for determining health priorities.
Introduction
‘‘What cannot be counted simply doesn’t count, and so we systematically
ignore large and important areas of concern.’’ — Ida Hoos, 1979 [1]. This
statementisparticularlyrelevanttoassessingtheimpactofneglected
tropical diseases (NTDs) on the world’s burden of disability. Last
year’s Disease Control Priorities Project asked ‘‘How much health
will a million dollars buy?’’ [2]. Because of flaws in the disability-
adjusted life year (DALY)system that we use for countingup disease
burdens, the answer must be ‘‘We really don’t know.’’
Two recent reviews [3,4] and a linked viewpoint article [5]
published in PLoS Neglected Tropical Diseases have introduced readers
to the controversies surrounding the merits and demerits of the
World Health Organization (WHO)–World Bank’s 1996 Global
Burden of Disease (GBD) program (Box 1) [6], as well as its
current plans for its revision as GBD 2005 under the auspices of
the Bill and Melinda Gates Foundation [3]. The problem of
inaccurate disease-burden assessments is particularly acute for the
diseases now characterized as neglected—in short, the NTDs
[7,8]. NTDs are chronic infections, including all helminthiases and
many protozoal, bacterial, and fungal infections that are common
among disadvantaged populations who live in less-developed
nations. By contrast, NTDs are quite rare in the more affluent
countries of the developed world.
Why are the NTDs ‘‘neglected’’ diseases? The question stems in
large part from the use of the DALY (Box 2) as a health metric in
policy planning, and the inadequate job done by the ongoing GBD
programs in capturing the health and economic burden caused by
NTDs in less-developed countries.
Brief History
The heart of the GBD assessments, which were developed in the
1980s and early 1990s as a health-sector priorities collaboration
between the WHO and the World Bank [3,6], was the use of a new
construct, the DALY (Box 2). The aim in developing the DALYwas
to objectively quantify and compare the aggregate regional and
worldwide health burdens created by many different disease states.
One purpose of the DALY formulation was to create a scalable
measure of disease impact for all health states, whereby an average
disease impact per person could be assessed for any individual
condition. Then, by knowing the total number of affected persons
and the duration of the disease, the global ‘‘burden of disease’’
could be summed for that condition. This DALY approach and its
ranking tables were believed to provide a more fair comparison of
disease burdens, because the approach to ranking of diseases was
believed to be nonsubjective, reflecting societal consensus, and
avoiding the potential biases that had been involved in expert
assessments of individual diseases [9]. The GBD program’s
ultimate agenda was to identify and rank preventable causes of
injury and disease, which in turn was expected to lead to more
effective implementation of strategies for disease control and
prevention [10]. As we shall see, this goal was only partially met.
DALY Drawbacks
The thesis of our current critique is that the design and use of
the DALY involve inherent flaws that result in a systematic
undervaluation of NTDs in world health. As we see it, there are
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the burden of disease caused by NTDs, as follows:
N A. By intentionally avoiding the ‘‘patient perspective,’’ the
DALY system excluded local context as a modifier of disease
impact.
N B. Many of the most common chronic complications of NTDs
were overlooked as part of the evaluation and weighting of
NTD-associated disabilities.
N C. In an effort to avoid overcounting actual life-years, the
DALY scoring system did not address the reality of shared
disabilities in the presence of comorbidities or concurrent
infections.
In addition, despite the laudable intent of the original GBD
program, serious criticisms of the DALY framework have come
from many other sectors, including objections based on philo-
sophical and ethical concerns about its approach to quantifying
and discounting the value of disabled life [11–18]. Yet, despite
these many cogent criticisms, no truly substantive changes have
been made to the DALY system, and the use (or abuse) of the
DALY metric has continued virtually unchanged since its
introduction in the 1990s. A revision of the GBD (GBD 2005
[3,4]) is in progress, and it is appropriate to re-address these issues
in detail.
The DALY framers’ initial intention was not that the DALY
valuation should serve as a ‘‘norm’’ [9], yet the DALY has become
normative because many health policy-makers and their funding
partners use the DALY as their only measure of disease impact in
programmatic analyses [11]. In essence, although most DALY
users are not familiar with how a DALY is calculated, the DALY
has become the primary value used to prioritize international
investments in disease control [2].
To use a home-based analogy, DALY valuations determine
whether it is a luxury or a necessity to spend available monies to treat
human NTDs. If the DALY estimates are wrong, then the
unfortunate consequence is that policy-makers’ decisions about
funding research or treatment programs for NTDs will undoubt-
edly be wrong as well.
Some Specifics—The DALY Calculation
At heart, the DALY is a mathematical construct that models the
health impact of individual diseases and allows them to be
compared in various rankings (e.g., health economists’ league
tables). As with all such constructs, a number of simplifying choices
and assumptions went into the creation of the DALY [18]. Not all
of these assumptions were made explicit in the initial adoption of
the DALY system (Box 3). Because they do not fully mirror reality,
mathematical models, like roadmaps, are always caricatures, and
in some senses wrong [19]. Despite their deficiencies, some models
can be useful in our attempts to address specific complex
Box 1. The GBD
Rationale for the Global Burden of Disease
initiative ,1991
N Societies need to make decisions about their provision
of health services.
N Policy makers must be aware of comparative disease
burdens and the injuries and the risk factors that cause
them.
N We need to understand the impact that modifying risk
factors can have on global disease burden.
N Consensus must be reached about how to quantify the
‘‘importance’’ of risk factors in a way that is comparable
across nations.
From Lopez et al. Global Burden of Disease and Risk
Factors, 2006 [69].
Box 2. The DALY
DALY=Disability-Adjusted Life Year
N A time-based measurement unit (metric) for estimation
the health burden caused by different diseases
N Meant to be interchangeable and equivalent across all
locations and cultures
N The ‘‘Like-as-Like’’ philosophy
Background
N Newly invented in the 1990s
N Developed by the Global Burden of Disease (GBD)
Program [9]
N Initially funded by the WHO and the World Bank
N Current revisions facilitated by funding from the Bill and
Melinda Gates Foundation
Formula: the DALY=YLLs+YLDs
N The DALY is a composite metric calculated from the sum
of Years of Life Lost (YLLs) and Years Lived with
Disability (YLDs) for any disease.
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D=disability weight L=duration of disability
a=age of onset of the disability r=the discount rate
(0.03)
b=the age-weighting parameter (b=0.04)
C=adjustment constant (0.1658)
K=the age-weighting modulation factor (K=1)
N YLDs Simplified=(duration of disease)6(preva-
lence)6(disability weight)6(age weight)6(future
discount)
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breakthrough [10].
Is the DALY truly useful in prioritizing health programs? From
the NTD perspective, there is a suite of problems concerning
many dimensions of the DALY that restrict its usefulness for
making economic decisions for NTD control.
Controversial Choices That Went into the Creation
of the DALY
The disability weighting scheme for the burden of
nonlethal conditions
Most NTDs fall into the nonlethal category. That is, they are
health states caused by communicable diseases in which
impairment occurs because of long-term, disease-related inflam-
mation. These infections only rarely cause sufficiently severe
morbidity that they result in premature death [20].
The DALY calculation for nonlethal conditions is based on a
years-lost-to-disability (YLD) calculation, using a disability weight
(DW) that is intended to reflect the relative impact due to ill health
from that particular disease during the period it afflicts an
individual patient [21]. With time- and age-discounting adjust-
ments, the DALY burden for a given disease reflects the sum of the
number of people with that disease, multiplied by the time spent in
that disease state, multiplied by the DW value (Box 2). Calculation
of an accurate DALY value implies that one can quantify an
accurate measure of disease impact (i.e., DW), as well as an
accurate estimate of disease incidence and duration, or of current
prevalence.
DWs for the DALY system were determined by panels of
nonexpert, highly educated participants assembled during the
initial GBD programs of the late 1980s and early 1990s [9]. Their
DW scores were assigned using an established (and, some might
argue, nonintuitive [22]) health economics technique called the
‘‘person trade-off’’ (PTO) method (Box 4). The group’s choices
were benchmarked against a ladder of 22 indicator conditions that
had been previously ranked by the same group or by other
nonexpert groups (Figure 1). In assigning DWs, capsule scenarios
of each disease state were provided to the PTO groups in order to
guide their discussions. Where the group’s choices disagreed,
particularly between the two PTO methods, a group leader or
facilitator required them to come to a consensus score for each
condition. The resulting single point estimate for the DW is
expressed on a scale from 0 to 1, where 0 denotes perfect health
and 1 is death [9].
We posit that, while the PTO methods perhaps fits well with
established economic theory about consumer preferences, from
the health practitioner’s and patient’s perspectives, the PTO
approach appears exceptionally awkward and unrealistic [22]. In
the first series of questions (known as the PTO1 protocol),
participants are asked to trade years of life of healthy individuals
for the life extension of individuals in different disease states, i.e.,
‘‘1 year of life for 1000 healthy individuals, or 1 year of life for
2000 blind individuals’’ [9]. In the subsequent PTO2 protocol,
participants are asked to trade years of life extension in healthy
individuals for years of life after morbidity alleviation (cure) for N
individuals in a given disabling health state. Through additional
group leader questioning and forced consensus of the DW-scoring
groups, the answers from the two protocols are reconciled, and are
then held to reflect the impact of this disease under ‘‘average social
conditions’’ for the world at large [9].
For the GBD framers, the DW derived in this fashion is believed
to reflect a ‘‘filtered consensus’’ of societal views about the impact
of individual disease states [9]. Although the PTO is an apparently
systematic and ‘‘value-free’’ approach grounded in economic
practice, the assignment of DWs is, in fact, largely subjective. Who
were the scoring panels, and how were they constituted and
assembled? Who were the facilitators? Ustun and colleagues [23]
have since systematically re-examined morbidity rankings for 17
conditions in 14 different countries, and noted significant
differences between countries in their rankings for 13/17
conditions, with the most pronounced differences for the most
stigmatizing illness, HIV/AIDS.
The details of GBD DW estimation have not been published in
the peer-reviewed literature, although GBD literature [9] indicates
that, because of the difficult nature of the PTO exercise, the panels
had to be composed of highly educated individuals. ‘‘Training’’ to
use the PTO and the enforced consensus among groups
undoubtedly means that the perspectives of the group leaders
and DALY designers were consciously or unconsciously imposed
upon the DW ranking system. We see a strong possibility that the
‘‘filtered consensus’’ in fact reflected the individual and cultural
biases of the panels and of the GBD facilitators themselves
[11,18,24]. Without additional validation, published DW values
have undoubtedly enshrined prevalent prejudices (or the frequent-
ly misinformed ‘‘common knowledge’’) about individual disease
Box 3. Hidden Assumptions of the DALY
Approach
1. There is an ‘‘average’’ disability for each disease state that
is the same in all settings [9].
2. There is a linear association between resource invest-
ment in a control program and the improvement of
disease burden [10].
3. We assume that the ‘‘health consumer’’ is well informed
and behaves rationally in making choices [47].
Box 4. Example of the Person Trade-off
Process—PTO Exercise 1
N You are a decision maker who has enough money to buy
only one of two mutually exclusive health interventions:
Intervention A or Intervention B.
N Intervention A will extend the life of 1,000 healthy
(non-disabled) individuals for exactly one year.
# If you purchase intervention A, you will extend their
lives for one year, at which point they will all die.
# If you do not purchase intervention A, they will all
die today.
N Intervention B will extend the life of N disabled
individuals for exactly 1 year; if you do purchase
intervention B, they will die at the end of one year.
# The alternative use of your scarce resources is
Intervention B; if you do buy Intervention B, your
disabled individuals will live for one year, at which
point they will all die.
# If you do not buy intervention B, they will all die
today.
N What is your value for N?
See [9] for details.
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valuations, the DWs have not been revisited or revised since their
initial publication in 1996.
Can there be a single, ‘‘average’’ DW for a given health
condition that is suitable worldwide for health burden calcula-
tions? Where significant population stratification exists, and risk
for disease varies strongly among these strata, good statistical
practice says that there can be no valid global average [25]. For NTDs,
socioeconomic status (SES) modifies or confounds the lifetime risk
of acquiring infection, meaning that poor communities jointly
suffer more from disease-associated health burden. At the same
time, other aspects of poverty serve as ‘‘effect modifiers’’ that
worsen the impact of infection and restrict access to care. Where
such significant stratum-related differences exist, the appropriate
approach is to provide stratum-specific DWs, or create a weighting
system that adjusts the DW for local SES. While it is not
technically feasible to have a separate DW for every disease in
every location [13], it would be highly appropriate in the next
iteration of GBD (GBD 2005 [3]) to use local levels of poverty as
an adjustor for disease DW and in its estimates of local, regional,
and national disability impact. Like others, we believe that
evidence-based adjustment of DWs for disease context [23] will
be an essential step in creating more accurate GBD valuations
[23,26].
There is concern that revision of one or only a few DWs would
unbalance the GBD rankings and possibly exceptionalize or
overvalue selected diseases. In a WHO-requested re-review of the
burden of disease due to schistosomiasis, the evaluators’ conclusion
was that ‘‘…it is unlikely that more accurate estimates would
significantly change the ranking of schistosomiasis burden…’’ [27].
The implication was that revision of the GBD league tables was
not required. Yet, it is important to see that in a health economics
and policy planning environment where ‘‘cost per DALY averted’’
[2] drives many health policy decisions, having an accurate DW
assessment would be an essential tool for making valid cost-related
and policy judgments. Failure to adjust GBD calculations for
location will result in a continued overvaluation of the ‘‘impor-
tance’’ of noncommunicable diseases (the primary disease burden
of wealthier countries) with a significant undervaluation of the
significance of communicable diseases (including the NTDs) that
remain a dominant health burden for developing countries [18].
The inherent bias of the original GBD in favor of noncommu-
nicable diseases has been carried into the current Disease Control
Priorities Project [28], resulting in serious undervaluation of the
importance of communicable disease control in current policy
discussions.
Confusion about what is included in the diagnosis of an
NTD
As Mathers et al. put forward in their recent review [3], ‘‘…the
impact of highly prevalent diseases with smaller levels of morbidity
has not been well measured [in the GBD system]…’’. Hence, DWs
due to NTDs created by the PTO process are problematic
because, upon reflection, the scenarios used to determine disability
in NTDs must not have reflected the full health impact of these
conditions. The published DWs for the NTDs suggest to us that
their scenarios were based on a limited understanding of the NTD-
associated health states, or on an artificially restricted definition of
these disease entities.
Where NTDs are prevalent, the bulk of their disease burden is
in the form of low-level, chronic morbidity. While this situation
might seem negligible to someone without experience of this group
of diseases, it must be remembered that most NTDs persist for
years (at least half a lifetime) and continue to affect personal health
and performance status for decades, even after infection is cleared.
Health evaluations in certain areas of Japan, China, and North
Africa where schistosomiasis transmission has ended indicate there
is a significant long-term disease impact of ‘‘post-transmission
schistosomiasis’’ [29] that must be addressed in health planning. In
view of the large numbers of people who carry NTDs and the long
duration of NTD effects, the aggregate years of healthy life lost to
chronic NTDs must be large. Yet the DALY values presented for
most NTDs in the GBD tables do not reflect this reality. Why
should this be so?
NTDs often present in the context of multiple coinfections.
Polyparasitism is a fact of life where most NTDs occur [30–32]. As
such, it has been difficult to disaggregate the ‘‘attributable risk’’
belonging to individual pathogens when we consider the causation
of infection-associated morbidities [33]. Where complications such
as anemia or malnutrition were recognized, inherent problems in
Figure 1. The DALY Person-Trade-Off Method of Disability Weight Determination.
doi:10.1371/journal.pntd.0000209.g001
Review
www.plosntds.org 4 2008 | Volume 2 | Issue 3 | e209determining cause-specific attributable risk led to these health- and
performance-significant outcomes being disaggregated from the
PTO scenarios and therefore from the assigned DWs of many of
the NTDs [34]. However, if properly valued and included in
DALY calculations, these more ‘‘subtle’’ morbidities could, in fact,
make up the bulk of prevalent morbidity and disability for many
chronic NTDs.
Part of the problem with the available data on NTD-related
morbidity is due to significant limitations in the design of past
population-based surveys [26]. Where resources are limited, study
sample size tends to be small. Large clinical effects and clinical
outcomes unique to individual diseases were easy to measure in
small surveys [35]. However, more ‘‘subtle’’ pathologies, and those
having mixed etiology were much harder to measure precisely,
and often when they were found to be ‘‘not statistically significant’’
they were ignored (in a classic type II error) or dismissed as
clinically unimportant [36,37].
We posit that the GBD specifically did not want to overcount
DALYs. That is, in their overall schema, there could not be more
life-years and DALYs reported as lost than there were life-years
lived by the global population. This ‘‘no overcount’’ rule appears
to have led the framers to disaggregate important comorbidities
such as anemia, diarrhea, growth stunting, and cognitive
impairment from many of the disease outcome assessments [34].
However, it can be seen as fundamental flaw of the DALY system
that its ‘‘disease’’ categories are based on a classification system
that includes both etiologic disorders and undifferentiated
syndromes (e.g., ‘‘anemia’’ and ‘‘infertility’’) as separate disease
entities. The system that the GBD used, the International
Classification of Diseases, ninth edition (ICD-9), is a convenient
off-the-shelf classification system for reporting health statistics, but
it is seriously deficient in defining preventable causes of disease, as
the GBD originally set out to do.
In medical practice, it is ethically unacceptable to leave a patient
with only a syndromic diagnosis such as ‘‘anemia’’ or ‘‘growth
stunting,’’ without making a concerted effort to establish the
underlying etiologic (causal) diagnosis. In like fashion, it is
inappropriate for the DALY system to disaggregate NTDs from
their common infection-associated morbidities, including the
syndromes of anemia, growth stunting, and cognitive impairment.
In disaggregating these morbid complications from their infectious
causes, the DWs assigned to specific NTDs are thus mistakenly
cheapened. When NTDs are viewed merely in this limited fashion,
they appear ‘‘unimportant’’ when compared to more acute or
more lethal disorders. It is noteworthy that the GBD insisted on
redistributing any deaths reported as due to ‘‘[s]ymptoms, signs
and ill-defined conditions,’’ reclassifying them into known ICD
groupings [34], yet it failed to determine ‘‘attributable burden’’ for
disability due to most nonlethal syndromic conditions [38]. This
devaluation, entrenched by the GBD ‘‘…because we were unable
to locate sufficient evidence on the relative risk…’’ [38] is then (as
part of the DALY scores) imputed to reflect societal preference [9]
and, as such, functionally enshrines the ‘‘neglect’’ of the NTDs in
health policy.
It is well known that anemia and the other GBD-listed
syndromes have many distinct preventable causes, including the
NTDs [39,40], which need to be identified, clearly defined, and
appropriately treated with specific remedies. We suggest that every
effort should be made to estimate the pathogen-specific attribut-
able fraction [41] of these undifferentiated syndromes in order to
appropriately reassign their disability burden to specific pathogens,
which, in turn, represent the truly preventable disease etiologies.
Certainly, improved diagnostics may be needed to more
accurately determine who is infected with NTDs and to better
define how much disease is attributable to each pathogen.
Where concurrent infections occur, it will be important to
determine whether infection with any NTD is sufficient (alone) for
morbidity development, or if multiple infections have additive or
synergistic (multiplicative) effects. Population-based studies are in
progress to measure these interaction effects. In the meantime, it
would be more appropriate to consider a combined NTD or a
‘‘polyparasitism’’ category as an operational diagnosis for disease
burden rankings, rather than leave anemia, infertility, etc., as
separate ‘‘diagnoses’’ in the GBD tables.
Doctrinal views of the asymmetric effects of poverty on
disease
‘‘Poverty is a lot like childbirth—you know it is going to hurt before it
happens, but you’ll never know how much until you experience it.’’ J. K.
Rowling, 2002 [42]. This quotation from an author who was once
plunged into poverty, and later became one of the wealthiest
women in the UK, highlights the very important differences
between the theoretical contemplation of poverty and the actual
experience of living with poverty [17].
Although in epidemiologic studies, location and environment
have long been known to be important effect modifiers in disease
formation, the GBD intentionally excluded patient context as a
factor in the calculation of disease burden [11]. This decision was
seen as necessary to create an interchangeable (fungible) unit of
disease burden (i.e., the DALY) that could apply to all areas of the
world, and could be used to ‘‘fairly’’ rank diseases by their
‘‘average’’ health burden [9]. The GBD framers rationalized their
decision to avoid disease-context considerations on the basis of a
controversial ‘‘like-as-like’’ moral argument [9]. The crux of the
argument was that any disease should be seen as having the same
impact on individual performance no matter where the disease
occurs. Furthermore, any weighting or location-specific adjust-
ment of disease burden was felt to lead to unwarranted
exceptionalization of individual conditions, directly or indirectly
contributing to a ‘‘welfarist’’ bias in disease burden assessments
and indirectly contributing to bias in health policy prioritization
[9]. However, as previously discussed, where significant popula-
tion stratification occurs, as with wealth disparity, the heteroge-
neity of groups means that there are, in fact, two or more
populations to evaluate, and there can be no ‘‘average’’ health
burden impact.
Taking the GBD formulation of the DALY construct in its own
historical context, one can infer that the individual-focused,
antiwelfare agenda predominant in the US and UK government
policies during the 1980s and 1990s may well have driven this
decision to remove context from disease burden assessment. The
free-market agendas popular at the time were based on laissez-
faire economic theories that emphasize the importance of
individual-level choices in determining success, while frequently
denying a significant role of group-level factors, or ‘‘society,’’ in
modifying life events. [43] Despite many counterarguments
asserting that the contextualization of disease is imperative to
the understanding of disease burden [11–13,17], the environmen-
tal aspects of disability formation were excluded from the GBD
system. In addition, although public health has long been viewed
as a ‘‘common good’’ that requires collective or government-level
decision-making [44], it is surprising that the strong influence of
group-level factors in disease formation was not incorporated into
the GBD assessments. The context of disease is particularly
germane when we consider the well-recognized additive or
multiplicative roles played by both individual-level and group-
Review
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outcomes [45,46].
With regard to context, the ‘‘like as like’’ argument of the GBD
formulation is assumed to be egalitarian, in that burden of disease is
identical for the same disease process for any individual, regardless
of location or socioeconomic status. In practical terms, the ‘‘like as
like’’ position is meant to ensure that the ‘‘currency’’ of disease
burden is interchangeable, universally consistent, and comparable
cross-culturally. DALY proponents argue that it is the best available
system for assessing the global burden of disease and setting disease
control priorities. Reidpath [12] asks, however, whether a
paraplegic person in Niger has the same disability as a paraplegic
personinAustralia,wheremultiplesupport systems existto facilitate
personal function. The answer is quite clearly no, yet this glaringly
obvious asymmetry is not addressed in the GBD system.
Poverty-Related Challenges for the GBD DALY
System
The presence of regional-, household-, and individual-level
poverty has many important numerical effects on the estimation of
DALY values for the NTDs.
A. The availability of adequate epidemiologic and vital statistics -
is highly inconsistent from country to country and from region to
region, tending to be the most inaccurate where resources are most
scarce [34]. Records of population size and mortality are
incomplete, especially in regions with little infrastructure, where
the NTDs are frequently most prevalent. Where hospitals and
clinics are not accessible, accurate measures morbidity and
mortality from NTDs can be difficult to obtain. For most sub-
Saharan African countries, GBD burden has been extrapolated
from the scant data available from other locations, meaning
estimates will be only approximate (i.e., wrong), with a strong
tendency towards underestimation of disease burden. In facing the
context-specific effect of inadequate data availability, the GBD is
probably overemphasizing the burden of diseases prominent in
developedcountries,wheregoodepidemiologicaldataareavailable,
and undervaluing the burden of disease in developing countries.
B. The use of age-weighting factors in DALY calculations is
highly controversial. Despite the egalitarian ‘‘like as like’’ stance of
the GBD (see reference [6] for further detail), the weight attributed
to morbidity or mortality is not equal across all human age groups
[11]. Disease occurring among individuals in the range of 20–40
years of age is given the highest effective DW by this weighting,
and disease among younger or older individuals counts for much
less. The GBD’s rationale is said to reflect ‘‘societal preference,’’
relating to an individual’s productive capacity at different stages of
life [9,16]. Generally, it is assumed that the very young and the
very old are dependent on the middle-aged for their care and
subsistence; thus the loss of a year of healthy life in middle age is
likely to have greater societal consequences [47].
However, the framework for age weighting does not take into
consideration the highly significant cross-cultural variation in
productive economic and social roles, and is biased toward a
model of life stages only as they are known in developed economies
[17,48]. It is typical in non-Western cultures that children
contribute substantially to household productivity as early as 4
years of age via child care and food production. For example,
Mikea children of southwestern Madagascar contribute nearly
enough foraged goods to the household to support their own
caloric intake [49]. Similarly, in many cultures, the elderly do not
retire or become dependent on younger workers within their
society, but remain productive contributors to society [48]. Thus,
in a developing economy where cash income is scarce, work starts
at age 4, and life expectancy is 46 years, then the age-weighting
system of the DALY calculation would clearly not reflect the
‘‘societal preference’’ for the value of any life years lived or gained
by health interventions.
C. Not all morbidity comes to clinical attention, especially
where health-care resources are limited. In the setting of poverty,
Figure 2. ‘‘Asymmetrical’’ or Nonlinear Outlook on Program Costs and Health Gains. To someone in the setting of severe poverty (income
, $1 per day), the gain or loss of a single health or performance-related dollar will appear substantially more important than it will to a middle-
income policymaker.
doi:10.1371/journal.pntd.0000209.g002
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because in poor rural settings, hard physical labor is the
predominant mode of survival. Small losses in productivity are
highly leveraged in terms of individual and household productivity
(Figure 2), and are economically more important to subsistence
farmers and herders than to workers in more developed
economies. This again raises the question as to whether PTO
focus groups can serve as adequate proxies in making health care
decisions for persons with NTDs. It is an established economic
principle that the value of an economic transaction is determined
by the utility of the purchase to the consumer alone. If PTO
committees do not understand the impact of chronic illness in the
context of poverty, they should not be the ones valuing the impact
of NTDs. If PTO committees are, in fact, representing the values
of the donors (or other payors), then the DALY is no longer a
positivist ‘‘value-free’’ metric, as claimed in the GBD program’s
description and goals [9].
The socioenvironmental structure in which an individual lives
dictates the capacity to which the individual is able to be functional
and productive with a given disease, and thus also dictates the
burden ensuing from the inability to function with disease within
society [12]. There are many misconceptions about the impact of
NTDs on daily life; for example, schistosomiasis infection is
significantly associated with subclinical morbidities such as caloric
undernutrition, exercise intolerance, fatigue, diarrhea, and
abdominal pain [26], all of which can be interrelated and
contribute to loss of productivity [50]. The relationship between
NTDs and loss of productivity is supported by other studies of
helminth infections that have found infection to be associated with
decreased physical function [51], decreased productivity [52], and
decreased wage-earning capacity in later adulthood in developing
countries [50]. Anemia does not have to be severe to be disabling.
Likewise, mild ‘‘chronic disease’’ anemia is significant in terms of
lowered endurance, income [53], and worsened birth outcomes
[54]. Similarly, undernutrition does not have to be severe to be
disabling [55].
D. Due to nonlinear quantitative factors, common cost-
effectiveness evaluations may fail to be relevant in the setting of
the ‘‘poverty trap’’ [56]. In standard cost-effectiveness analysis
(CEA), there is a tacit assumption of linearity between the size of
health-care investment and the size of health benefits obtained
(Figure 3) [57]. As DALYs are frequently used as outcomes or
‘‘utilities’’ in this type of exercise, a traditional CEA will prove
invalid for NTDs for two reasons: first, because of misclassification
of the nature and size of disease burden (DW), and second, because
of the nonlinear effects of poverty on reversibility of disease burden.
Will an increment in investment for NTD control yield a
predictable suite of DALY benefits for all treated populations?
Probably not. Local variation in asymmetric poverty effects will
vary program effects on health and performance, which means
that expected number of ‘‘DALYs averted’’ [10] may or may not
be achieved for a given investment (Figure 3). Because of the
correlated confounding effects of local poverty [56], the rate of
DALY improvement after program interventions may vary
considerably between poor and middle-income locales.
E. Finally, alternative patient preference approaches (time
trade-off, willingness-to-pay) will not work unless the alternative
health states are truly understood. Patients with NTDs will not be
well-informed consumers (Box 3) if they are not aware of the
alternative health states to be considered. Wherever chronic NTDs
are part of the fabric of daily life and people carry infection and its
late consequences for most of their lives, can they appreciate
disease impact without experiencing the difference? Can they be
truly informed consumers? Here, education level and understand-
ing of disease causation can play a highly significant role. In
particular, one can see that willingness-to-pay and time trade-off
exercises for disability ranking are likely to be invalid in mostly
noncash economies and in settings where limited lifespan (i.e., less
than 50 years) is usual. Results for these setting may be
significantly different than for developed economies.
Overview and Summary
‘‘If our knowledge is poor, a mathematical model will poorly reproduce
reality – this is actually a useful implication because it can verify whether our
knowledge about the infection is sufficiently complete.’’ — Duerr, Dietz,
and Eichner 2005 [58].
Overall, we can see that there is no ‘‘average disability’’ for
many NTDs, but because just such a value is used in the complex
DALY exercise [9], any current GBD comparisons reflecting on
the ‘‘priority’’ of certain diseases over others [2] remain extremely
dubious. In previous sections, we have identified a number of
critical choices that result in inherent deficiencies in the current
DALY valuations, particularly for the diseases of developing
countries now referred to as the NTDs. Because the DALY
calculations are the underpinnings of the GBD program’s disease
Figure 3. In the Context of Poverty There Are Nonlinear Differences in the Efficacy of Treatment on Health Outcomes. Individual
poverty and residence in an impoverished environment can combine synergistically to impair improvement from single health interventions. (See
reference [56].)
doi:10.1371/journal.pntd.0000209.g003
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priorities for controlling the diseases of the poor.
As the NTDs are given low priority, the net result of such
‘‘merely technical’’ DALY errors is to enshrine chronic NTD
transmission and infection as the status quo, creating a situation in
which chronic diseases and their related disabilities become an
expected part of life [59,60]. As a result, NTD-affected
communities are less economically productive, and impoverished
communities are less and less likely to break out of the ‘‘poverty
trap,’’ a vicious cycle of negative economic growth related to
individual and group-level poverty effects [56]. Achieving the
poverty reduction objectives of the Millennium Development
Goals will require that serious attention be paid to the far-reaching
effects of NTDs—these neglected diseases are transmitted as a
result of poverty and, because of their chronic disabling effects,
remain a continuing cause of poverty.
Gwatkin and colleagues [18] point out the fact that although the
GBD program suggests a reordering of priorities, stressing that
noncommunicable diseases of older age groups are becoming
more prevalent than communicable diseases [2], this supposed
shift in prevalence does not reflect the reality of health issues in
most poor areas. If health investments favor noncommunicable
disease control (based on GBD DALY rankings), it turns out that
rich areas stand to benefit much more from this investment (an
increase of 5.3 years of life expectancy) than do poor countries (1.4
years). In Gwatkin’s revised analysis of World Bank and GBD
data, an investment that instead reduces communicable diseases
would gain an additional 4 years of life expectancy for the world’s
poorest 20%. The substantial difference in life expectancy
outcomes shows that it is still a priority to invest in control of
communicable diseases, including the NTDs.
Future Directions and Recommendations
Ultimately, we see that the GBD’s ‘‘like as like’’ philosophy is not
fair to those living in poverty. In particular, the approach to
disability weighting used in the current GBD DALY system fails to
accurately measure the health burden of NTDs. Can we repair the
DALY to make it more accurately reflect the burden of disease in
developing countries, or should we simply replace the DALY with
a better health metric?
In 1996, the DALY approach was seen as a useful ‘‘first
approximation’’ for mapping disease burden, both worldwide and
across regions or countries. Its obvious limitations, particularly
regarding DW determinations, make its current use in cost-
effectiveness estimations outdated and unreliable. For the new
GBD 2005 initiative, we should not accept that the original DALY
DW estimates [6] reflect the world’s ‘‘societal view’’ of NTD
burden [17], nor should we use DALY rankings to define the
‘‘importance’’ of any disease. Those 1996 DALY estimates clearly
reflect the cultural viewpoints of those who constructed the DALY,
and not those of other cultures or of the NTD-endemic
populations. If the disease control world insists on using a
DALY-type metric for their comparisons, then a substantial
revision, particularly with adjustment for disease and disability
context [11], is essential. At the least, a weighted adjustment for
individual or local poverty factors would be appropriate. If the
DALY system remains in use, and it is to provide a valid
measurement tool, then its GBD 2005 revision must include
system-wide changes in the GBD calculations that address the
concerns raised in this paper.
We believe that it would be better to use formal patient-based
determination of quality-of-life (QoL) and quality-adjusted life-
year (QALY [57]) for determination of losses due to NTD
diagnoses in endemic locations, as has been recently done for
chronic schistosomiasis japonica in China [61] and schistosomiasis
mansoni in Kenya [62]. QALY values are estimated from
preference-based health-related QoL interviews administered to
groups of patients or to members of the general population [21].
QoL-related visual analog scales [63] and the short EuroQol 5D
questionnaire [61,64] have already been adapted for use in Africa
and China. Determining QALY impacts for NTDs would take
extensive effort in terms of fieldwork, but putting all things into
perspective, it has been 20 years since the first DALY program was
developed, and many of its systemic flaws (that we and others [11–
13,16,26,47,65] have identified) have not been addressed since
then. Use of a patient-based QoL assessment such as the QALY
would get beyond the narrow, Northern (or developed-economy)
slant in the disease burden assessments used in current versions of
the GBD program, and provide a more realistic idea of the impact
of NTDs on world health.
The recommended approach to restructuring the DALY should
go well beyond efforts to improve incidence and prevalence data.
While we applaud those technical corrections, the following are
the minimal changes that are needed.
A. The DALY weights should be made internally consistent—
for example, the impact of infertility should not vary whether it is
postsepsis or due to sexually transmitted diseases [6].
B. Age weighting should not be used to value heath outcomes
[11].
C. Clinical syndromes such as anemia and malnutrition are not
diagnoses, and should not be confused with preventable causative
etiologies. Where overlap occurs in terms of causation for such
disabling syndromes, we need to recapture the attributable burden
associated with all potentially preventable causes, including NTDs
[26].
D. For chronic disabling conditions, DWs should be evidence-
based, reflecting already available data on the physical and
personal performance impacts of these diseases [26]. Scenarios for
DW weighting of NTDs should be vetted both by patients and by
disease specialists who know these diseases. GBD program
facilitators should not assume that their own knowledge of a disease
reflects the world’s view of a disease’s burden, nor should an
affluent PTO panel assume that they encompass a patient’s
perspective on disease burden in the context of poverty.
E. DWs should be adjusted for health resource abundance in
the location/context where the disease occurs [11].
As a first step, we recommend a revaluation of disease-
specific DWs based on available evidence and conditional
prevalence of disease-related morbidities that occur with NTD
infections [26,65,66]. It will be important to include the very
important domains of physical productivity and the culture-
dependent, stigma-causing disease outcomes such as infertility,
low fecundity, loss of marriage prospects, and loss of employability
that were clearly not addressed in the initial GBD assessments
[14,66].
Where attributable risk for identified morbidities cannot be
disaggregated, an attempt should be made to examine the joint
NTD causation of syndromic disabilities, especially anemia and
undernutrition. These two important NTD-related outcomes
cannot be left as catchall ‘‘diagnoses’’ if the benefits of available
drug-treatment and transmission-prevention measures are to be
fairly assessed. Given that many NTD control programs are now
providing multiple-drug administration with agents that provide
treatment of several NTD infections simultaneously [8,67], it
would be appropriate to evaluate the combined burden of a
common ‘‘basket’’ of NTD infections such as hookworm disease,
ascariasis, and lymphatic filariasis as an operational NTD disease
Review
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cost-effectiveness [68].
Overall, there needs to be a regular reassessment of disease
burden as local developmental conditions change. This should go
well beyond just updating population and prevalence data. We
favor the use of QALYs as more comprehensive, ‘‘societal’’ view of
disease impact, particularly one that captures the disease
externalities related to poverty that were not appreciated or
captured by the standard DALY valuation approaches [57,61]. It
is hoped that the GBD 2005 project will pay heed to these issues.
Otherwise, the new, ‘‘second-generation’’ DALY system of the
new GBD 2005 will be as deficient as the first Global Burden of
Disease program in assessing NTD-related health burden.
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